GNDM
Apr 11, 2019
Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion
Inozyme Pharma Raises USD 67 Million in Series A2 Financing Inozyme Pharma- a Boston-based biotechnology company, solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The company plans to use this funding to progress its lead asset INZ-701, into clinical trials. INZ-701...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
